Jae Moon Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jae Moon Shin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Bo Ri Kim
Department of Dermatology, Seoul National University Bundang Hospital , Seongnam
3 shared publications - Chang-Hun Huh
Department of Dermatology Seoul National University Bundang Hospital Seongnam Korea
2 shared publications - Jee Yoon Park
Department of Dermatology Seoul National University Bundang Hospital Seongnam Korea
2 shared publications - Minsu Kim
Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine , Seongnam
2 shared publications - Chong Won Choi
Department of Dermatology, Seoul National University Bundang Hospital , Seongnam
1 shared publication - Gyoohwan Jung
Department of Urology, Hanyang University Seoul Hospital, Seoul, Korea
1 shared publication
Latest Publications
- 11 February 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4) , 673-682
Nail Involvement Is a Key Determinant of Treatment Persistence in Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic relapsing inflammatory skin disorder predominantly affecting the palms and soles. Despite the continued use of oral systemic agents, real‐world data on their durability and treatment patterns in PPP remain limited. To investigate the treatment patterns, drug survival, and clinical factors associated with treatment persistence in patients with PPP receiving oral systemic therapies. We conducted a retrospective cohort study of patients diagnosed with PPP at a tertiary care referral center in Korea between January 2010 and August 2023. Patients were categorized according to the initial oral agent prescribed—cyclosporine, acitretin, or methotrexate. Treatment trajectories were assessed using predefined criteria, and 12‐month drug survival was evaluated. Clinical predictors of treatment non‐persistence were identified using Cox proportional hazards regression analysis. Among 374 patients, 192 received oral systemic therapy (cyclosporine, n = 110; acitretin, n = 72; methotrexate, n = 8). Cyclosporine was the most commonly prescribed first‐line agent. Median drug survival was the longest for cyclosporine, followed by methotrexate and acitretin ( p = 0.15). Nail involvement was associated with greater persistence (HR = 0.617; 95% CI: 0.444–0.857; p = 0.004), whereas baseline hypertension increased discontinuation risk (HR = 1.492; 95% CI: 1.015–2.195; p = 0.042). Discontinuation patterns differed by agent: cyclosporine was often stopped early due to adverse events but remained durable in patients who tolerated it; acitretin was associated with early and persistent adverse events, with well‐controlled disease emerging as a later reason for cessation; and methotrexate showed sustained use beyond 6 months, with most discontinuations attributed to well‐controlled disease. This study highlights the heterogeneous treatment trajectories and variable drug survival among oral agents for PPP. Nail involvement and hypertension may be key clinical predictors of persistence. These findings support individualized treatment approaches to improve long‐term management of PPP.
- 11 February 2026
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (4) , 673-682
Nail Involvement Is a Key Determinant of Treatment Persistence in Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic relapsing inflammatory skin disorder predominantly affecting the palms and soles. Despite the continued use of oral systemic agents, real‐world data on their durability and treatment patterns in PPP remain limited. To investigate the treatment patterns, drug survival, and clinical factors associated with treatment persistence in patients with PPP receiving oral systemic therapies. We conducted a retrospective cohort study of patients diagnosed with PPP at a tertiary care referral center in Korea between January 2010 and August 2023. Patients were categorized according to the initial oral agent prescribed—cyclosporine, acitretin, or methotrexate. Treatment trajectories were assessed using predefined criteria, and 12‐month drug survival was evaluated. Clinical predictors of treatment non‐persistence were identified using Cox proportional hazards regression analysis. Among 374 patients, 192 received oral systemic therapy (cyclosporine, n = 110; acitretin, n = 72; methotrexate, n = 8). Cyclosporine was the most commonly prescribed first‐line agent. Median drug survival was the longest for cyclosporine, followed by methotrexate and acitretin ( p = 0.15). Nail involvement was associated with greater persistence (HR = 0.617; 95% CI: 0.444–0.857; p = 0.004), whereas baseline hypertension increased discontinuation risk (HR = 1.492; 95% CI: 1.015–2.195; p = 0.042). Discontinuation patterns differed by agent: cyclosporine was often stopped early due to adverse events but remained durable in patients who tolerated it; acitretin was associated with early and persistent adverse events, with well‐controlled disease emerging as a later reason for cessation; and methotrexate showed sustained use beyond 6 months, with most discontinuations attributed to well‐controlled disease. This study highlights the heterogeneous treatment trajectories and variable drug survival among oral agents for PPP. Nail involvement and hypertension may be key clinical predictors of persistence. These findings support individualized treatment approaches to improve long‐term management of PPP.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 4887762
Changes in Scalp Condition Following the Use of a Moisturizer Containing Celastrol and Cichorium intybus Root Extract: A Prospective Clinical Trial Utilizing Artificial Intelligence–Based Scalp Assessment
Background: Scalp conditions such as dandruff and pruritus are common even among otherwise healthy individuals and have been associated with impaired skin barrier function and abnormal epidermal differentiation. Moisturizers containing celastrol and Cichorium intybus root extract have previously demonstrated clinical benefits in patients with psoriasis, a condition characterized by similar pathogenic abnormalities. Objective: To evaluate changes in scalp condition following the use of a scalp moisturizer containing celastrol and C . intybus root extract and to assess the clinical utility of an artificial intelligence–based scalp assessment system (SPI‐AI) in detecting treatment‐related improvements. Methods: This prospective clinical trial enrolled 23 participants with scalp conditions, including erythema, dryness, scaling, and dandruff, who applied the moisturizer once daily for 4 weeks. The primary outcome was the change in scalp condition, assessed using SPI‐AI. Secondary outcomes included biophysical parameters (erythema index, stratum corneum hydration, and transepidermal water loss [TEWL]) and patient‐reported symptoms assessed using the visual analog scale (VAS). Results: At Week 4, the total SPI‐AI score showed significant improvement (23.7 ± 4.5 to 20.5 ± 4.3, p = 0.005), with the erythema (9.5 ± 3.5 to 7.6 ± 2.9, p = 0.003) and folliculitis (4.0 ± 1.6 to 2.7 ± 1.1, p = 0.008) components exhibiting the most pronounced changes. In parallel, patient‐reported symptoms improved significantly (5.9 ± 1.8 to 3.7 ± 1.7, p < 0.001). Among the secondary outcomes, erythema index decreased significantly at Week 2 (139.3 ± 37.3 to 131.4 ± 40.4, p = 0.020), whereas no significant changes were observed in stratum corneum hydration or TEWL. Treatment compliance was high without serious adverse events reported. Conclusions: A scalp moisturizer containing celastrol and C. intybus root extract significantly improved scalp condition and exhibited a favorable safety profile. SPI‐AI sensitively detected early changes in scalp condition in a clinical trial setting. Trial Registration: ClinicalTrials.gov Identifier: NCT07459023
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 4887762
Open AccessChanges in Scalp Condition Following the Use of a Moisturizer Containing Celastrol and Cichorium intybus Root Extract: A Prospective Clinical Trial Utilizing Artificial Intelligence–Based Scalp Assessment
Background: Scalp conditions such as dandruff and pruritus are common even among otherwise healthy individuals and have been associated with impaired skin barrier function and abnormal epidermal differentiation. Moisturizers containing celastrol and Cichorium intybus root extract have previously demonstrated clinical benefits in patients with psoriasis, a condition characterized by similar pathogenic abnormalities. Objective: To evaluate changes in scalp condition following the use of a scalp moisturizer containing celastrol and C . intybus root extract and to assess the clinical utility of an artificial intelligence–based scalp assessment system (SPI‐AI) in detecting treatment‐related improvements. Methods: This prospective clinical trial enrolled 23 participants with scalp conditions, including erythema, dryness, scaling, and dandruff, who applied the moisturizer once daily for 4 weeks. The primary outcome was the change in scalp condition, assessed using SPI‐AI. Secondary outcomes included biophysical parameters (erythema index, stratum corneum hydration, and transepidermal water loss [TEWL]) and patient‐reported symptoms assessed using the visual analog scale (VAS). Results: At Week 4, the total SPI‐AI score showed significant improvement (23.7 ± 4.5 to 20.5 ± 4.3, p = 0.005), with the erythema (9.5 ± 3.5 to 7.6 ± 2.9, p = 0.003) and folliculitis (4.0 ± 1.6 to 2.7 ± 1.1, p = 0.008) components exhibiting the most pronounced changes. In parallel, patient‐reported symptoms improved significantly (5.9 ± 1.8 to 3.7 ± 1.7, p < 0.001). Among the secondary outcomes, erythema index decreased significantly at Week 2 (139.3 ± 37.3 to 131.4 ± 40.4, p = 0.020), whereas no significant changes were observed in stratum corneum hydration or TEWL. Treatment compliance was high without serious adverse events reported. Conclusions: A scalp moisturizer containing celastrol and C. intybus root extract significantly improved scalp condition and exhibited a favorable safety profile. SPI‐AI sensitively detected early changes in scalp condition in a clinical trial setting. Trial Registration: ClinicalTrials.gov Identifier: NCT07459023
- Open Access
- 23 July 2024
- Published by Wiley in International Wound Journal
- Vol. 21 (7) , e70004
Comparison of the wound healing and complications of zipper type closure adhesive tape and stapler for surgical wound suture: A randomized control, single‐centre, open‐label trial
Xkin closure is a newly developed medical suture device for lacerations and surgical wounds that can reduce scarring, pain and the risk of infection compared with conventional sutures or staplers. A randomized controlled study was performed to compare the wound healing effects and complications of Xkin closure with stapler closure. Fifty patients who underwent robot‐assisted radical prostatectomy for prostate cancer were randomly assigned. Only the wound above the navel, which was extended to take out the prostate was targeted. The wound was examined at 2, 6 and 12 weeks after surgery, and the modified Vancouver Scar Scale (mVSS), scar height and side effects were assessed with a 3D skin analyser. Forty‐six patients (23 Xkin, 23 Stapler) were analysed. The mVSS scores, vascularity and pliability were significantly lower in the Xkin group compared with the stapler group at the 12‐week follow‐up. No significant differences in the maximum peak and depth of the scars were detected between the two groups using 3D photographs at 12 weeks. Xkin is an effective wound closure method for improving scar outcomes. This method is expected to be widely used for surgical wounds and lacerations caused by trauma in daily life.
- 23 July 2024
- Published by Wiley in International Wound Journal
- Vol. 21 (7) , e70004
Open AccessComparison of the wound healing and complications of zipper type closure adhesive tape and stapler for surgical wound suture: A randomized control, single‐centre, open‐label trial
Xkin closure is a newly developed medical suture device for lacerations and surgical wounds that can reduce scarring, pain and the risk of infection compared with conventional sutures or staplers. A randomized controlled study was performed to compare the wound healing effects and complications of Xkin closure with stapler closure. Fifty patients who underwent robot‐assisted radical prostatectomy for prostate cancer were randomly assigned. Only the wound above the navel, which was extended to take out the prostate was targeted. The wound was examined at 2, 6 and 12 weeks after surgery, and the modified Vancouver Scar Scale (mVSS), scar height and side effects were assessed with a 3D skin analyser. Forty‐six patients (23 Xkin, 23 Stapler) were analysed. The mVSS scores, vascularity and pliability were significantly lower in the Xkin group compared with the stapler group at the 12‐week follow‐up. No significant differences in the maximum peak and depth of the scars were detected between the two groups using 3D photographs at 12 weeks. Xkin is an effective wound closure method for improving scar outcomes. This method is expected to be widely used for surgical wounds and lacerations caused by trauma in daily life.